Physician profile
Stuart E Sinoff
NPI 1659488989
$4,841.66
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $1,748 · 2021: $121 · 2022: $125 · 2023: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $318 · Travel and Lodging: $13.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.91 |
| Travel and Lodging | $13.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $613.04 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $483.33 | 2019-2023 | Soliris |
| Genzyme Corporation | $382.21 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $341.05 | 2019-2021 | |
| Ucb, INC. | $315.41 | 2019-2023 | |
| Emd Serono, INC. | $270.84 | 2019-2020 | |
| Acorda Therapeutics, INC | $226.27 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $216.78 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $203.89 | 2019-2021 | |
| Lilly USA, LLC | $193.06 | 2019-2020 | |
| Allergan, INC. | $188.21 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $176.22 | 2019-2020 | |
| Genentech, INC. | $143.85 | 2020 | |
| Neurocrine Biosciences, INC. | $139.91 | 2019-2020 | |
| Biogen, INC. | $138.55 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.85 | 2019 | |
| Avanir Pharmaceuticals, INC. | $84.43 | 2019-2020 | |
| Genentech USA, INC. | $82.01 | 2019 | |
| Amgen INC. | $70.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $58.06 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $53.62 | 2019-2020 | |
| Lundbeck LLC | $46.07 | 2019-2020 | |
| Csl Behring | $37.79 | 2019 | |
| Kyowa Kirin, INC. | $37.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.81 | 2020 | |
| Mdd US Operations, LLC | $35.66 | 2019 | |
| Abbott Laboratories | $34.67 | 2019 | |
| Amneal Pharmaceuticals LLC | $31.14 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $30.89 | 2020 | |
| Medtronic Vascular, INC. | $20.02 | 2019 | |
| Ge Healthcare | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Sinoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.